• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

RSNA never ceases to amaze, even after a year of news

Article

All year long, we at Diagnostic Imaging write about important radiology issues. You might think that by the time the RSNA meeting rolls around, we would have covered just about everything. Well, in a sense, we have. But the reality is that the "big show" never ceases to amaze us. Each year, forecasted trends don't materialize, surprise trends sneak up, and the usual number of boom and bust predictions either boom . . . or bust.

The clinical buzz this year was 64-slice CT. At the 2004 meeting, only a handful of papers discussed this new technology. This year, the bolus ran over.

Utilization topics received their due, but the tone was quieter this year, mainly due to the government siding with the American College of Radiology on this issue.

And compared with the loud splash in September made by the release of the DMIST study results, breast imaging sessions at the RSNA meeting might have been viewed as little more than background noise. But breast tomosynthesis changed that. While far from mature, breast tomosynthesis appears to be here to stay.

Molecular imaging got the requisite push-and then some. In one lecture, radiologists were chastened not to become too complacent in analyzing anatomic structures. The future, we're told, is in cellular therapies and nanotechnology, but you wouldn't know that based on attendance figures for sessions tied to molecular topics.

But if I had to sum up the meeting in three words, they'd be: CAD, CAD, CAD. Computer-aided detection is everywhere, and some luminaries worry that computers will make human interpreters obsolete. That may be the very scare needed to fill seats in the molecular imaging sessions.

C.P. Kaiser, news editor of Diagnostic Imaging

Recent Videos
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.